K
Kenneth I. Kaitin
Researcher at Tufts Center for the Study of Drug Development
Publications - 95
Citations - 2723
Kenneth I. Kaitin is an academic researcher from Tufts Center for the Study of Drug Development. The author has contributed to research in topics: Drug development & Pharmaceutical industry. The author has an hindex of 28, co-authored 92 publications receiving 2518 citations. Previous affiliations of Kenneth I. Kaitin include Tufts University & Stanford University.
Papers
More filters
Journal ArticleDOI
Deconstructing the Drug Development Process: The New Face of Innovation
TL;DR: The pharmaceutical sector, as currently structured, is unable to deliver enough new products to market to generate revenues sufficient to sustain its own growth.
Journal ArticleDOI
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
TL;DR: The results indicate that, whereas total approvals are currently at a 25‐year low, the percentage of priority products is nearly 50% of the total—a 30‐year high and provides the underpinnings of a fundamental shift in the structure of the research‐based industry.
Journal ArticleDOI
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective
TL;DR: The therapeutic classes most commonly associated with safety discontinuations were the nonsteroidal anti‐inflammatory drugs, vasodilators, and antidepressants, and U.S. companies or their foreign subsidiaries were involved as originators (patent‐holders and/or developers) of approximately 40% of the drugs discontinued for safety reasons.
Journal ArticleDOI
Assessing the impact of protocol design changes on clinical trial performance.
TL;DR: The results of this study indicate that the number of unique procedures and the frequency of procedures per protocol have increased at the annual rate of 6.5% and 8.7%, respectively, during the time period measured, and implications for simplifying protocol designs and minimizing negative effects on study conduct performance are discussed.
Journal ArticleDOI
Muscarinic cholinergic receptors and the canine model of narcolepsy.
Thomas S. Kilduff,S. Scott Bowersox,Kenneth I. Kaitin,Theodore L. Baker,Theodore L. Baker,Roland D. Ciaranello,William C. Dement +6 more
TL;DR: This up-regulation of brainstem cholinergic receptors suggests a problem with release of acetylcholine, which, together with previous reports of an impairment of dopamine release, may be indicative of a fundamental membrane problem in narcolepsy.